Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2008

View Archived Issues

Studies show surfen to be a heparan sulfate antagonist

Merck & Co reports results from studies with cathepsin K inhibitor odanacatib

Recent patents report novel therapeutic agents for HCV infection

New anticancer agents described in recent patents

Kaken launches new formulation Adofeed Pap 80 mg in Japan

Novel agents for respiratory and allergic disorders disclosed in recent patent literature

New antiviral drug company formed, Cocrystal Discovery

Omrix enrolls initial 90 patients for interim analysis in Fibrin Pad phase II trial

Paion presents update on phase I CNS-7056 study

SciClone presents promising phase II results for SCV-07 in hepatitis C

Clinical data for rheumatoid arthritis drug candidate VEL-0230 presented

Akesis expands preclinical safety program for AKP-020

Novel TNF-alpha antagonists developed at Ensemble Discovery

Athersys provides update on ATHX-105 development and results of recent studies

Preliminary results for AMG-386 in combination with other antiangiogenic agents in solid tumors

Belinostat in combination with carboplatin and paclitaxel evaluated in phase I/II cancer studies

Cornerstone initiates CPI-613 trial for the treatment of cancer

Metabasis initiates MB-07803 trial in patients with type 2 diabetes

Oramed commences phase IIa oral insulin trials in patients with type 1 diabetes

PolyMedix starts dosing in phase I novel anticoagulant antagonist trial

Baxter initiates phase III Gammagard Liquid trial for the treatment of AD

MAA for lacosamide in diabetic neuropathic pain withdrawn; product launched in E.U. for seizures

CHMP issues positive opinion for Kuvan for hyperphenylalaninemia

Abstral receives U.K. marketing authorization for breakthrough cancer pain

Aveo initiates first SCH-900105 trial in patients with solid tumors and lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...